We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LNZ100, an aceclidine-based eye drop, demonstrated a ...

In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lumevoq demonstrated continued vision improvement in ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...

Both trials met the primary and secondary near vision improvement endpoints. Treatment with an aceclidine-based eye drop was found to improve near vision in patients with presbyopia, according to ...

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...

One of the best ways to improve eyesight is consuming enough vitamin A which can be found in foods like carrots, sweet potatoes, and spinach. You can also protect your eyesight from further damage by ...

As we age, our eyesight naturally declines but a new study has found exposing our retinas to short bursts of deep red light can help deteriorating vision. The research shows just three minutes of ...

Patients with presbyopia had consistent and durable vision improvement across multiple doses of a combination eye drop solution, a large retrospective review showed. From 69% to 99% of patients had ...

Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.